Search

Your search keyword '"Mu, Zhaomei"' showing total 139 results
Start Over Author "Mu, Zhaomei"
139 results on '"Mu, Zhaomei"'

1. Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors

Author

Wang, Chun, Mu, Zhaomei, Ye, Zhong, Zhang, Zhenchao, Abu-Khalaf, Maysa M., Silver, Daniel P., Palazzo, Juan P., Jagannathan, Geetha, Fellin, Frederick M., Bhattacharya, Saveri, Jaslow, Rebecca J., Tsangaris, Theodore N., Berger, Adam, Neupane, Manish, Cescon, Terrence P., Lopez, AnaMaria, Yao, Kaelan, Chong, Weelic, Lu, Brian, Myers, Ronald E., Hou, Lifang, Wei, Qiang, Li, Bingshan, Cristofanilli, Massimo, and Yang, Hushan

Published
2020
Full Text
View/download PDF

2. Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA

Author

Ye, Zhong, Wang, Chun, Wan, Shaogui, Mu, Zhaomei, Zhang, Zhenchao, Abu-Khalaf, Maysa M., Fellin, Frederick M., Silver, Daniel P., Neupane, Manish, Jaslow, Rebecca J., Bhattacharya, Saveri, Tsangaris, Theodore N., Chervoneva, Inna, Berger, Adam, Austin, Laura, Palazzo, Juan P., Myers, Ronald E., Pancholy, Neha, Toorkey, Darayus, Yao, Kaelan, Krall, Max, Li, Xiuling, Chen, Xiaobing, Fu, Xiuhong, Xing, Jinliang, Hou, Lifang, Wei, Qiang, Li, Bingshan, Cristofanilli, Massimo, and Yang, Hushan

Published
2019
Full Text
View/download PDF

3. Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer

Author

Gerratana, Lorenzo, Davis, Andrew A., Zhang, Qiang, Basile, Debora, Rossi, Giovanna, Strickland, Kimberly, Franzoni, Alessandra, Allegri, Lorenzo, Mu, Zhaomei, Zhang, Youbin, Flaum, Lisa E., Damante, Giuseppe, Gradishar, William John, Platanias, Leonidas C., Behdad, Amir, Yang, Hushan, Puglisi, Fabio, and Cristofanilli, Massimo

Published
2021
Full Text
View/download PDF

7. Supplementary Figure S4: ATF3 represses AR transcriptional target PSA expression in LNCaP cells after AD and edelfosine treatment. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity

Author

Udayakumar, Thirupandiyur S., primary, Stoyanova, Radka, primary, Shareef, Mohammed M., primary, Mu, Zhaomei, primary, Philip, Sakhi, primary, Burnstein, Kerry L., primary, and Pollack, Alan, primary

Published
2023
Full Text
View/download PDF

8. Supplementary Figure S5: Elevated ATF3 after AD and edelfosine treatments inhibits AR promoter activity in LNCaP cells. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity

Author

Udayakumar, Thirupandiyur S., primary, Stoyanova, Radka, primary, Shareef, Mohammed M., primary, Mu, Zhaomei, primary, Philip, Sakhi, primary, Burnstein, Kerry L., primary, and Pollack, Alan, primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figure S2: ATF3 knockdown via siATF3 inhibits apoptosis in VCaP cells after AD and edelfosine treatment. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity

Author

Udayakumar, Thirupandiyur S., primary, Stoyanova, Radka, primary, Shareef, Mohammed M., primary, Mu, Zhaomei, primary, Philip, Sakhi, primary, Burnstein, Kerry L., primary, and Pollack, Alan, primary

Published
2023
Full Text
View/download PDF

12. Supplemental Table 1-3 from CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion

Author

Jiao, Xuanmao, primary, Velasco-Velázquez, Marco A., primary, Wang, Min, primary, Li, Zhiping, primary, Rui, Hallgeir, primary, Peck, Amy R., primary, Korkola, James E., primary, Chen, Xuelian, primary, Xu, Shaohua, primary, DuHadaway, James B., primary, Guerrero-Rodriguez, Sandra, primary, Addya, Sankar, primary, Sicoli, Daniela, primary, Mu, Zhaomei, primary, Zhang, Gang, primary, Stucky, Andres, primary, Zhang, Xi, primary, Cristofanilli, Massimo, primary, Fatatis, Alessandro, primary, Gray, Joe W., primary, Zhong, Jiang F., primary, Prendergast, George C., primary, and Pestell, Richard G., primary

Published
2023
Full Text
View/download PDF

13. Data from CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion

Author

Jiao, Xuanmao, primary, Velasco-Velázquez, Marco A., primary, Wang, Min, primary, Li, Zhiping, primary, Rui, Hallgeir, primary, Peck, Amy R., primary, Korkola, James E., primary, Chen, Xuelian, primary, Xu, Shaohua, primary, DuHadaway, James B., primary, Guerrero-Rodriguez, Sandra, primary, Addya, Sankar, primary, Sicoli, Daniela, primary, Mu, Zhaomei, primary, Zhang, Gang, primary, Stucky, Andres, primary, Zhang, Xi, primary, Cristofanilli, Massimo, primary, Fatatis, Alessandro, primary, Gray, Joe W., primary, Zhong, Jiang F., primary, Prendergast, George C., primary, and Pestell, Richard G., primary

Published
2023
Full Text
View/download PDF

14. Legends of Supplemental Figure 1-11 from CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion

Author

Jiao, Xuanmao, primary, Velasco-Velázquez, Marco A., primary, Wang, Min, primary, Li, Zhiping, primary, Rui, Hallgeir, primary, Peck, Amy R., primary, Korkola, James E., primary, Chen, Xuelian, primary, Xu, Shaohua, primary, DuHadaway, James B., primary, Guerrero-Rodriguez, Sandra, primary, Addya, Sankar, primary, Sicoli, Daniela, primary, Mu, Zhaomei, primary, Zhang, Gang, primary, Stucky, Andres, primary, Zhang, Xi, primary, Cristofanilli, Massimo, primary, Fatatis, Alessandro, primary, Gray, Joe W., primary, Zhong, Jiang F., primary, Prendergast, George C., primary, and Pestell, Richard G., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Table S1. from Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer

Author

Rossi, Giovanna, primary, Mu, Zhaomei, primary, Rademaker, Alfred W., primary, Austin, Laura K., primary, Strickland, Kimberly S., primary, Costa, Ricardo Lima Barros, primary, Nagy, Rebecca J., primary, Zagonel, Vittorina, primary, Taxter, Timothy J., primary, Behdad, Amir, primary, Wehbe, Firas H., primary, Platanias, Leonidas C., primary, Gradishar, William J., primary, and Cristofanilli, Massimo, primary

Published
2023
Full Text
View/download PDF

16. Supplemental Figure 1-11 from CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion

Author

Jiao, Xuanmao, primary, Velasco-Velázquez, Marco A., primary, Wang, Min, primary, Li, Zhiping, primary, Rui, Hallgeir, primary, Peck, Amy R., primary, Korkola, James E., primary, Chen, Xuelian, primary, Xu, Shaohua, primary, DuHadaway, James B., primary, Guerrero-Rodriguez, Sandra, primary, Addya, Sankar, primary, Sicoli, Daniela, primary, Mu, Zhaomei, primary, Zhang, Gang, primary, Stucky, Andres, primary, Zhang, Xi, primary, Cristofanilli, Massimo, primary, Fatatis, Alessandro, primary, Gray, Joe W., primary, Zhong, Jiang F., primary, Prendergast, George C., primary, and Pestell, Richard G., primary

Published
2023
Full Text
View/download PDF

22. Presence of anaplastic lymphoma kinase in inflammatory breast cancer

Author

Robertson, Fredika M, Petricoin III, Emanuel F, Van Laere, Steven J, Bertucci, Francois, Chu, Khoi, Fernandez, Sandra V, Mu, Zhaomei, Alpaugh, Katherine, Pei, Jianming, Circo, Rita, Wulfkuhle, Julia, Ye, Zaiming, Boley, Kimberly M, Liu, Hui, Moraes, Ricardo, Zhang, Xuejun, DeMaria, Ruggero, Barsky, Sanford H, Sun, Guoxian, and Cristofanilli, Massimo

Published
2013
Full Text
View/download PDF

23. Inflammatory breast cancer (IBC): clues for targeted therapies

Author

Fernandez, Sandra V., Robertson, Fredika M., Pei, Jianming, Aburto-Chumpitaz, Lucy, Mu, Zhaomei, Chu, Khoi, Alpaugh, R. K., Huang, Yong, Cao, Yu, Ye, Zaiming, Cai, Kathy Q., Boley, Kimberly M., Klein-Szanto, Andres J., Devarajan, Karthik, Addya, Sankar, and Cristofanilli, Massimo

Published
2013
Full Text
View/download PDF

28. Abstract 2646: The liquid biopsy network in advanced breast cancer (ABC): Benchmarking the prognostic role of circulating tumor DNA (ctDNA) to the goal standard circulating tumor cells (CTCs) enumeration

Author

Gerratana, Lorenzo, primary, Davis, Andrew A., additional, Rossi, Giovanna, additional, Strickland, Kimberly, additional, Mu, Zhaomei, additional, Flaum, Lisa, additional, Gradishar, William J., additional, Santa-Maria, Cesar, additional, Yang, Hushan, additional, and Cristofanilli, Massimo, additional

Published
2018
Full Text
View/download PDF

29. Circulating tumor cells enumeration (CTCs) and circulating tumor DNA (ctDNA): Clinical and molecular features of “rapidly progressing” stage IV disease (Stage IVprog).

Author

Gerratana, Lorenzo, primary, Zhang, Qiang, additional, Davis, Andrew A., additional, Zhang, Youbin, additional, Rossi, Giovanna, additional, Strickland, Kimberly, additional, Mu, Zhaomei, additional, Flaum, Lisa E., additional, Santa-Maria, Cesar Augusto, additional, Yang, Hushan, additional, Gradishar, William John, additional, Platanias, Leonidas C, additional, and Cristofanilli, Massimo, additional

Published
2018
Full Text
View/download PDF

30. CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion

Author

Jiao, Xuanmao, primary, Velasco-Velázquez, Marco A., additional, Wang, Min, additional, Li, Zhiping, additional, Rui, Hallgeir, additional, Peck, Amy R., additional, Korkola, James E., additional, Chen, Xuelian, additional, Xu, Shaohua, additional, DuHadaway, James B., additional, Guerrero-Rodriguez, Sandra, additional, Addya, Sankar, additional, Sicoli, Daniela, additional, Mu, Zhaomei, additional, Zhang, Gang, additional, Stucky, Andres, additional, Zhang, Xi, additional, Cristofanilli, Massimo, additional, Fatatis, Alessandro, additional, Gray, Joe W., additional, Zhong, Jiang F., additional, Prendergast, George C., additional, and Pestell, Richard G., additional

Published
2018
Full Text
View/download PDF

31. Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer

Author

Rossi, Giovanna, primary, Mu, Zhaomei, additional, Rademaker, Alfred W., additional, Austin, Laura K., additional, Strickland, Kimberly S., additional, Costa, Ricardo Lima Barros, additional, Nagy, Rebecca J., additional, Zagonel, Vittorina, additional, Taxter, Timothy J., additional, Behdad, Amir, additional, Wehbe, Firas H., additional, Platanias, Leonidas C., additional, Gradishar, William J., additional, and Cristofanilli, Massimo, additional

Published
2018
Full Text
View/download PDF

32. Detection of activating estrogen receptor gene (ESR1) mutations in single circulating tumor cells

Author

Paolillo, Carmela, Mu, Zhaomei, Rossi, Giovanna, Schiewer, Matthew J., Nguyen, Thomas, Austin, Laura, Capoluongo, Ettore, Knudsen, Karen E., Cristofanilli, Massimo, Fortina, Paolo, Paolillo, Carmela, Mu, Zhaomei, Rossi, Giovanna, Schiewer, Matthew J., Nguyen, Thomas, Austin, Laura, Capoluongo, Ettore, Knudsen, Karen E., Cristofanilli, Massimo, and Fortina, Paolo

Abstract

Purpose: Early detection is essential for treatment plans before onset of metastatic disease. Our purpose was to demonstrate feasibility to detect and monitor estrogen receptor 1 (ESR1) gene mutations at the single circulating tumor cell (CTC) level in metastatic breast cancer (MBC). Experimental Design: We used a CTC molecular characterization approach to investigate heterogeneity of 14 hotspot mutations in ESR1 and their correlation with endocrine resistance. Combining the CellSearch and DEPArray technologies allowed recovery of 71 single CTCs and 12 WBC from 3 ER-positive MBC patients. Forty CTCs and 12 WBC were subjected to whole genome amplification by MALBAC and Sanger sequencing. Results: Among 3 selected patients, 2 had an ESR1 mutation (Y537). One showed two different ESR1 variants in a single CTC and another showed loss of heterozygosity. All mutations were detected in matched cell-free DNA (cfDNA). Furthermore, one had 2 serial blood samples analyzed and showed changes in both cfDNA and CTCs with emergence of mutations in ESR1 (Y537S and T570I), which has not been reported previously. Conclusions: CTCs are easily accessible biomarkers to monitor and better personalize management of patients with previously demonstrated ER-MBC who are progressing on endocrine therapy. We showed that single CTC analysis can yield important information on clonal heterogeneity and can be a source of discovery of novel and potential driver mutations. Finally, we also validate a workflow for liquid biopsy that will facilitate early detection of ESR1 mutations, the emergence of endocrine resistance and the choice of further target therapy. ©2017 AACR.

Published
2017

34. Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer.

Author

Mu, Zhaomei, Benali-Furet, Naoual, Uzan, Georges, Znaty, Anaëlle, Ye, Zhong, Paolillo, Carmela, Wang, Chun, Austin, Laura, Rossi, Giovanna, Fortina, Paolo, Yang, Hushan, Cristofanilli, Massimo, Mu, Zhaomei, Benali-Furet, Naoual, Uzan, Georges, Znaty, Anaëlle, Ye, Zhong, Paolillo, Carmela, Wang, Chun, Austin, Laura, Rossi, Giovanna, Fortina, Paolo, Yang, Hushan, and Cristofanilli, Massimo

Abstract

The availability of blood-based diagnostic testing using a non-invasive technique holds promise for real-time monitoring of disease progression and treatment selection. Circulating tumor cells (CTCs) have been used as a prognostic biomarker for the metastatic breast cancer (MBC). The molecular characterization of CTCs is fundamental to the phenotypic identification of malignant cells and description of the relevant genetic alterations that may change according to disease progression and therapy resistance. However, the molecular characterization of CTCs remains a challenge because of the rarity and heterogeneity of CTCs and technological difficulties in the enrichment, isolation and molecular characterization of CTCs. In this pilot study, we evaluated circulating tumor associated cells in one blood draw by size exclusion technology and cytological analysis. Among 30 prospectively enrolled MBC patients, CTCs, circulating tumor cell clusters (CTC clusters), CTCs of epithelial-mesenchymal transition (EMT) and cancer associated macrophage-like cells (CAMLs) were detected and analyzed. For molecular characterization of CTCs, size-exclusion method for CTC enrichment was tested in combination with DEPArray™ technology, which allows the recovery of single CTCs or pools of CTCs as a pure CTC sample for mutation analysis. Genomic mutations of TP53 and ESR1 were analyzed by targeted sequencing on isolated 7 CTCs from a patient with MBC. The results of genomic analysis showed heterozygous TP53 R248W mutation from one single CTC and pools of three CTCs, and homozygous TP53 R248W mutation from one single CTC and pools of two CTCs. Wild-type ESR1 was detected in the same isolated CTCs. The results of this study reveal that size-exclusion method can be used to enrich and identify circulating tumor associated cells, and enriched CTCs were characterized for genetic alterations in MBC patients, respectively.

Published
2016

35. A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone

Author

Lin, Jianqing, primary, Patel, Sheel A., additional, Sama, Ashwin R., additional, Hoffman-Censits, Jean H., additional, Kennedy, Brooke, additional, Kilpatrick, Deborah, additional, Ye, Zhong, additional, Yang, Hushan, additional, Mu, Zhaomei, additional, Leiby, Benjamin, additional, Lewis, Nancy, additional, Cristofanilli, Massimo, additional, and Kelly, William Kevin, additional

Published
2016
Full Text
View/download PDF

36. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer

Author

Wang, Chun, primary, Mu, Zhaomei, additional, Chervoneva, Inna, additional, Austin, Laura, additional, Ye, Zhong, additional, Rossi, Giovanna, additional, Palazzo, Juan P., additional, Sun, Carl, additional, Abu-Khalaf, Maysa, additional, Myers, Ronald E., additional, Zhu, Zhu, additional, Ba, Yanna, additional, Li, Bingshan, additional, Hou, Lifang, additional, Cristofanilli, Massimo, additional, and Yang, Hushan, additional

Published
2016
Full Text
View/download PDF

39. Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) longitudinal monitoring of metastatic breast cancer (MBC).

Author

Costa, Ricardo Lima Barros, primary, Rossi, Giovanna, additional, Mu, Zhaomei, additional, Austin, Laura Katherine, additional, Rademaker, Alfred, additional, Gradishar, William John, additional, Santa-Maria, Cesar Augusto, additional, Jain, Sarika, additional, Flaum, Lisa E., additional, Giles, Francis J., additional, Yang, Hushan, additional, and Cristofanilli, Massimo, additional

Published
2016
Full Text
View/download PDF

40. A phase I/II study of the investigational drug alisertib in combination with abiraterone and prednisone (AP) for patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on abiraterone.

Author

Lin, Jianqing, primary, Sama, Ashwin Reddy, additional, Hoffman-Censits, Jean H., additional, Kennedy, Brooke, additional, Kilpatrick, Deborah, additional, Ye, Zhong, additional, Yang, Hushan, additional, Mu, Zhaomei, additional, Leiby, Benjamin E, additional, Lewis, Nancy, additional, Cristofanilli, Massimo, additional, and Kelly, William Kevin, additional

Published
2016
Full Text
View/download PDF

42. Abstract 2788: Comprehensive high-depth target sequencing in circulating tumor DNAs of patients with inflammatory and non-inflammation breast cancers

Author

Yang, Hushan, primary, Zhong, Xue, additional, Wei, Qiang, additional, Mu, Zhaomei, additional, Ye, Zhong, additional, Lai, Yinzhi, additional, Lin, Huei-Wen, additional, Jaslow, Rebecca, additional, Avery, Tiffany, additional, Austin, Laura, additional, Sun, Zhaohui, additional, Lin, Shengrong, additional, Zhao, Grace, additional, Tang, Ling Fang, additional, Myers, Ronald E., additional, Palazzo, Juan P., additional, Biederman, Laura, additional, Li, Bingshan, additional, and Cristofanilli, Massimo, additional

Published
2015
Full Text
View/download PDF

47. Abstract P4-01-20: A novel microfluidic system for the detection, enumeration and molecular analysis of circulating tumor cells (CTCs) in metastatic breast cancer (MBC)

Author

Paolillo, Carmela, primary, Mu, Zhaomei, additional, Toss, Angela, additional, Gogoi, Priyadarshini, additional, Sepehri, Saedeh, additional, Zhou, Yi, additional, Handique, Kalyan, additional, Zhong, Ye, additional, Yang, Hushan, additional, Capoluongo, Ettore, additional, Cristofanilli, Massimo, additional, and Fortina, Paolo, additional

Published
2015
Full Text
View/download PDF

48. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.

Author

Mu, Zhaomei, Klinowska, Teresa, Dong, Xiaoshen, Foster, Emily, Womack, Chris, Fernandez, Sandra V, Cristofanilli, Massimo, Mu, Zhaomei, Klinowska, Teresa, Dong, Xiaoshen, Foster, Emily, Womack, Chris, Fernandez, Sandra V, and Cristofanilli, Massimo

Abstract

INTRODUCTION: Epidermal growth factor receptor (EGFR) overexpression has been associated with prognostic and predictive value in inflammatory breast cancer (IBC). Epidermal growth factor receptor 2 (HER2) overexpression is observed at a higher rate in IBC compared with noninflammatory breast cancer. Current clinically available anti-HER2 therapies are effective only in patients with HER2 amplified breast cancer, including IBC. AZD8931 is a novel small-molecule equipotent inhibitor of EGFR, HER2, and HER3 signaling. In this study, we investigated the antitumor activity of AZD8931 alone or in combination with paclitaxel using preclinical models of EGFR-overexpressed and HER2 non-amplified IBC cells. METHODS: Two IBC cell lines SUM149 and FC-IBC-02 derived from pleural effusion of an IBC patient were used in this study. Cell growth and apoptotic cell death were examined in vitro. For the in vivo tumor growth studies, IBC cells were orthotopically transplanted into the mammary fat pads of immunodeficient mice. AZD8931 was given by daily oral gavage at doses of 25 mg/kg, 5 days/week for 4 weeks. Paclitaxel was subcutaneously injected twice weekly. RESULTS: AZD8931 significantly suppressed cell growth of IBC cells and induced apoptosis of human IBC cells in vitro. Significantly, we showed that AZD8931 monotherapy inhibited xenograft growth and the combination of paclitaxel + AZD8931 was demonstrably more effective than paclitaxel or AZD8931 alone treatment at delaying tumor growth in vivo in orthotopic IBC models. CONCLUSION: AZD8931 single agent and in combination with paclitaxel demonstrated signal inhibition and antitumor activity in EGFR-overexpressed and HER2 non-amplified IBC models. These results suggest that AZD8931 may provide a novel therapeutic strategy for the treatment of IBC patients with HER2 non-amplified tumors.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results